IP Library Granted Patent US 7,323,329
Granted Patent B2
US 7,323,329 · App. 10/353,891 · Granted Jan 29, 2008

Methods for production of hyaluronic acid, and isolated strains of supercapsulated streptococci

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,323,329
App. No.
10/353,891
Granted
Jan 29, 2008
Kind
B2
Abstract

Isolated strains of supercapsulated streptococci band at a density of no greater than 1.03 g/cm 3 in a Percoll gradient and are capable of producing hyaluronic acid with molecular weight exceeding 6 million Da. Methods of producing high molecular weight hyaluronic acid employ a supercapsulated strain of streptococcus which bands at a density of no greater than 1.03 g/cm 3 in a Percoll gradient. Methods of selecting streptococcus strains capable of producing hyaluronic acid with a molecular weight exceeding 6 million Da comprise, inter alia, cultivating supercapsulated strains of streptococci which band at a density of no greater than 1.03 g/cm 3 in a Percoll gradient.

Claims (22)

1. An isolated strain of supercapsulated streptococci , wherein supercapsulated members of the strain have a density of no greater than 1.03 g/cm 3 and are capable of producing hyaluronic acid with molecular weight exceeding 6 million Da.

2. The isolated strain of supercapsulated streptococci according to claim 1 , wherein the supercapsulated strain is selected from the group consisting of supercapsulated group A streptococci and supercapsulated group C streptococci.

3. A method of producing high molecular weight hyaluronic acid, comprising the steps of:

(i) selecting the isolated strain of supercapsulated streptococcus of claim 1 ;

(ii) cultivating said strain at a temperature of 30 to 35° C. in a reactor under agitation conditions substantially free from shear forces and in a culture medium which is free of metal ions promoting the degradation of hyaluronic acid, does not release from the reactor metal ions promoting degradation of hyaluronic acid and has a pH in the range of 5.6 to 6.2, whereby hyaluronic acid is formed; and

(iii) purifying the hyaluronic acid formed in step (ii) from the culture medium to give hyaluronic acid with a molecular weight above six million Da.

4. The method according to claim 3 , wherein the culture medium is free of iron and copper.

5. The method according to claim 3 , wherein the culture medium has a pH in the range of 5.6 to 5.95.

6. The method according to claim 3 , wherein the supercapsulated strain is selected from the group consisting of supercapsulated group A streptococci and supercapsulated group C streptococci.

7. The method according to claim 6 , wherein the culture medium is free of iron and copper.

8. The method according to claim 6 , wherein the culture medium has a pH in the range of 5.6 to 5.95.

9. The method according to claim 3 , wherein the supercapsulated strain has been obtained by mutagenesis.

10. The method according to claim 9 , wherein the culture medium is free of iron and copper.

11. The method according to claim 9 , wherein the culture medium has a pH in the range of 5.6 to 5.95.

12. A method of selecting streptococcus strains capable of producing hyaluronic acid with a molecular weight exceeding six million Da, comprising the steps of:

(i) subjecting streptococci strains to mutagenesis, whereby mutated strains are obtained; and

selecting a mutated strain wherein supercapsulated members of the strain have a density of no greater than 1.03 g/cm 3 .

13. The method according to claim 12 , wherein the mutagenesis is chemical mutagenesis.

14. The method according to claim 13 , wherein the streptococci strains which are subjected to mutagenesis are selected from the group consisting of group A streptococci and group C streptococci.

15. The method according to claim 12 , wherein the supercapsulated members of the strain are capable of producing hyaluronic acid having a molecular weight exceeding 8 million Da but not greater than about 9.5 million Da.

16. The method according to claim 12 , wherein the supercapsulated members of the strain are capable of producing hyaluronic acid having a molecular weight exceeding 9 million Da but not greater than about 9.5 million Da.

17. The method according to claim 12 , wherein the streptococci strains which are subjected to mutagenesis are selected from the group consisting of group A streptococci and group C streptococci.

Assignments (7)
CHANGE OF NAME Recorded Dec 7, 2010
From: ADVANCED MEDICAL OPTICS UPPSALA AB
To: AMO UPPSALA AB
Reel/Frame 025461/0245 →
RELEASE OF SECURITY INTEREST AT REEL/FRAME NO. 14961/0242 Recorded Apr 4, 2007
From: BANK OF AMERICA, N.A.
To: ADVANCED MEDICAL OPTICS, INC.
Reel/Frame 019111/0871 →
CHANGE OF NAME Recorded Jan 31, 2006
From: PHARMACIA AKTIEBOLAG
To: PFIZER HEALTH AB
Reel/Frame 017089/0652 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 30, 2006
From: PFIZER HEALTH AB
To: HEALON AB
Reel/Frame 017083/0590 →
CHANGE OF NAME Recorded Jan 30, 2006
From: PHARMACIA AKTIEBOLAG
To: PFIZER HEALTH AB
Reel/Frame 017089/0292 →
CHANGE OF NAME Recorded Sep 30, 2005
From: HEALON AB
To: ADVANCED MEDICAL OPTICS UPPSALA AB
Reel/Frame 016614/0564 →
SECURITY AGREEMENT Recorded Aug 3, 2004
From: ADVANCED MEDICAL OPTICS, INC.
To: BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 014961/0242 →